Lupin Ltd. is planning to build up its activities in the Asia-Pacific region, while potential consolidation among domestic generic players in Japan, nudged along by government "encouragement", may also well be another trend to watch out for, senior executives from the major Indian generic firm have said.
INTERVIEW: Lupin Gears For APAC Push, Japan Generic Consolidation
Indian generic firm Lupin is gearing up for a significant business push in the Asia-Pacific area, with Japan as the kernel for developments in some key markets, the firm's top regional executives have indicated.
More from Focus On Asia
More from Scrip
• By
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies